Abstract
ICRF-187 was tested for cardioprotective activity in doxorubicin-treated mice and guinea pigs. Pretreatment with i.p. ICRF-187 caused a significant decrease in the indicence of i.v. doxorubicin-induced myocardial histological damage in the mouse. I.p. ICRF-187 did not, however, reduce the effect of i.p. doxorubicin on a functional myocardial effect of this antitumour drug, a reduced histamine responsiveness of right atria in vitro. These data suggest that ICRF-187 may not be specific for all the cardiac effects of doxorubicin.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Rights and permissions
About this article
Cite this article
Perkins, W., Schroeder, R., Carrano, R. et al. Effect of ICRF-187 on doxorubicin-induced myocardial effects in the mouse and guinea pig. Br J Cancer 46, 662–667 (1982). https://doi.org/10.1038/bjc.1982.251
Issue Date:
DOI: https://doi.org/10.1038/bjc.1982.251
This article is cited by
-
Insights into the coordination chemistry of antineoplastic doxorubicin with 3d-transition metal ions Zn2+, Cu2+, and VO2+: a study using well-calibrated thermodynamic cycles and chemical interaction quantum chemistry models
Journal of Computer-Aided Molecular Design (2023)
-
Protection by flavonoids against anthracycline cardiotoxicity: from chemistry to clinical trials
Cardiovascular Toxicology (2007)
-
Protectors against doxorubicin-induced cardiotoxicity: Flavonoids
Cell Biology and Toxicology (2007)
-
The cardioprotector ADR-529 and high-dose epirubicin given in combination with cyclophosphamide, 5-fluorouracil, and tamoxifen: a phase I study in metastatic breast cancer
Cancer Chemotherapy and Pharmacology (1994)
-
The pharmacokinetics of high-dose epirubicin and of the cardioprotector ADR-529 given together with cyclophosphamide, 5-fluorouracil, and tamoxifen in metastatic breast-cancer patients
Cancer Chemotherapy and Pharmacology (1994)
